anti-asthmatic

HSR6071 is a novel orally active and potent anti-allergic agent with inhibitory effects on passive cutaneous anaphylaxis. HSR6071 showed anti-asthmatic activity in a rat model of experimental asthma.

Nexopamil racemate((Rac)-Nexopamil) is a racemate of Nexopamil. The Nexopamil racemate has potential anti-asthmatic and anti-ulcer activity.

MCI826 is a potent and selective antagonist of P-glycoprotein (P-gp) and peptide leukotrienes (p-LTs), showing anti-asthmatic activity in a guinea pig model of advanced asthma.

RG 7152 is a leukotriene D4 antagonist with anti-asthmatic properties and can be used in the study of asthma.

Fluticasone furoate (Avamys) is a synthetic trifluorinated corticosteroid derived from fluticasone with a Kd of 0.3 nM. Fluticasone furoate has potent anti-inflammatory, anti-asthmatic activity, and low systemic exposure. Fluticasone furoate can be used as a nasal spray for studies about allergic rhinitis treatment.

RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells.

PNU 2 is an anti-asthmatic compound.

Suplatast Tosilate (IPD 1151T) is a novel capsular anti-asthmatic drug with an IC50 above 100 μM, inhibiting both IgE production and the synthesis of IL-4 and IL-5.

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

Minocromil is a new agent of Anti-asthmatic.

ISOCROMIL, a chromone compound, exhibits anti-allergic properties. It plays a significant role as a mediator release inhibitor in the treatment of passive cutaneous anaphylaxis reactions and is also important as an anti-asthmatic agent.

Histamine glutarimide is a novel small molecule agent functioning as an inhibitor of glutaminyl-peptide cyclotransferase (QPCT), which targets key inflammatory processes including eosinophilic migration and mast cell degranulation, Histamine glutarimide has demonstrated significant anti-asthmatic effects in various preclinical animal models of allergic asthma.

Amiterol, a phenylethylamine derivative, is an oral anti-asthmatic compound (bronchodilator).

MIDD0301 (GL-II-93) sodium is an orally active inhibitor of γ-aminobutyric acid type A receptors (GABAAR) and an anti-asthmatic agent. It shows bio- and immunotoxicological safety in mice without affecting circulating lymphocyte, monocyte, and granulocyte counts. MIDD0301 sodium demonstrates no significant adverse immune responses under repeated dosing and is more favorable than Prednisone. It relaxes histamine-contracted tracheal smooth muscle in guinea pigs and humans, making it a valuable candidate for research in bronchoconstriction-related diseases.

Ablukast (Ro 23-3544) is a leukotriene receptor antagonist that functions as an anti-asthmatic.

Albifylline is a xanthine derivates with anti-asthmatic activity. Albifylline may cause a significant reduction of shock-induced leukocyte adhesions to the sinusoidal endothelium in the liver after hemorrhagic shock. Albifylline also improves microvascula

Allosamidin, a chitinase inhibitor and typical secondary metabolite of Streptomyces, may be used as a pesticide and anti-asthmatic agent.

Parogrelil is a phosphodiesterase (PDE3 PDE5A) inhibitor potentially for the treatment of intermittent. Parogrelil suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. Parogrelil improves reduced walking

Schisandrin (Wuweizi alcohol-A) is a compound with anti-asthmatic, anti-cancer, and anti-inflammatory effects.

Naringenin chalcone (Isosalipurpol) has antiallergic activity Naringenin chalcone suppresses asthmatic symptoms by inhibiting Th2 cytokine production from CD4 T cells. Naringenin chalcone is a potent tomato flavonoid that improves adipocyte metabolic functions and exerts insulin-sensitizing effects by activating an adiponectin-related pathway. Naringenin chalcone exhibits anti-inflammatory properties by inhibiting the production of proinflammatory cytokines in the interaction between adipocytes and macrophages, may be useful for ameliorating the inflammatory changes in obese adipose tissue.

LASSBio-1632 is a novel anti-asthmatic lead candidate that selectively inhibits PDE4A and PDE4D isoenzymes, leading to the suppression of airway hyper-reactivity (AHR) and TNF-α production in lung tissue. With high experimental BBB permeability, LASSBio-1632 (7j) efficiently crosses the blood-brain barrier through passive diffusion [1].

Pitavastatin (NK-104) sodium is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase and an inducer of the hepatocyte low-density lipoprotein cholesterol (LDL-C) receptor. It inhibits acetate synthesis of cholesterol in HepG2 cells and exhibits anti-atherogenic, anti-osteoarthritic, anti-asthmatic, anti-tumour, neuroprotective, hepatoprotective, and nephroprotective effects.

Pranlukast hemihydrate (ONO-1078 hemihydrate) is a selective and potent leukotriene (LT) antagonist with anti-asthmatic activity that inhibits [3H]LTD4 and [3H]LTE4 binding to lung membranes and antagonizes LTC4-induced constriction of guinea-pig airways.Pranlukast hemihydrate is used in the study of asthma. Pranlukast hemihydrate is used in the study of asthma.

Zafirlukast (ICI 204219) is an orally active leukotriene D4 receptor (LTD4) antagonist (IC50=0.6 μM). Zafirlukast has anti-asthmatic, anti-inflammatory, and antimicrobial properties and is used in the prevention and treatment of asthma.